StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$3.09+0.26 (+9.19%)

Close on Nov 17, 2026Market cap $306.36MP/E –Yield –

X4 Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

X4 Pharmaceuticals's pe ratio was 0.8× on Jul 31, 2025.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jul 31, 20250.8×–

More X4 Pharmaceuticals figures

See a number that looks wrong?